Method for inhibiting bone resorption

Abstract

Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.

1 - 16 . (canceled)  
     
     
         17 . A method for treating or preventing osteoporosis in a mammal, said method comprising orally administering to said mammal a pharmaceutically effective amount of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof as a unit dosage according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.  
     
     
         18 . A method according to  claim 17  wherein said mammal is a human.  
     
     
         19 . A method according to  claim 18  wherein said dosing interval is once-weekly.  
     
     
         20 . A method according to  claim 19  wherein said unit dosage comprises from about 3.5 mg to about 200 mg, on an acid active basis, of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.  
     
     
         21 . A method according to  claim 20  wherein said unit dosage comprises about 35 mg, on an acid active basis, of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.  
     
     
         22 . A method according to  claim 20  wherein said unit dosage comprises about 40 mg, on an acid active basis, of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.  
     
     
         23 . A method according to  claim 20  wherein said unit dosage comprises about 45 mg, on an acid active basis, of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.  
     
     
         24 . A method according to  claim 20  wherein said unit dosage comprises about 50 mg, on an acid active basis, of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.  
     
     
         25 . A method according to  claim 19  wherein said unit dosage comprises about 1.5 to about 6000 μg/kg body weight of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.  
     
     
         26 . A method according to  claim 19  wherein said unit dosage comprises about 10 to about 2000 μg/kg body weight of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.  
     
     
         27 . A method according to any one of claims  17 - 26  wherein said unit dosage is in the form of a tablet.  
     
     
         28 . A method according to any one of claims  17 - 26  wherein said unit dosage is in the form of a capsule.  
     
     
         29 . A method according to any one of claims  17 - 26  wherein said unit dosage is in the form of a liquid.  
     
     
         30 . A pharmaceutical oral dosage form comprising, on an acid active basis, 50 mg to 200 mg of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof, as a unit dosage, wherein said dosage form is a tablet or a capsule.  
     
     
         31 . A pharmaceutical oral dosage form comprising, on an acid active basis, 100 mg, 150 mg, or 200 mg of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof, as a unit dosage, wherein said dosage form is a tablet or a capsule  
     
     
         32 . A pharmaceutical oral dosage form comprising, on an acid active basis, 100 mg or 150 mg of ibandronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof, as a unit dosage, wherein said dosage form is a tablet or a capsule.